在阿尔茨海默病药物治疗前一年,对多药和联合药物的匹配病例控制研究
Ali Alghamdi1, Stijn de Vos1, Jens Hj Bos1
1Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen, The Netherlands.
Journal of Alzheimer's disease : JAD
|January 10, 2025
概括
与没有阿尔茨海默氏症的人相比,阿尔茨海默氏症 (AD) 患者在诊断前多药的患病率更高. 这凸显了AD患者需要谨慎的药物管理的必要性.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是最常见的痴呆症,标志着粉样斑块和神经纤维状结.
- 人口老龄化增加了AD和并发症,往往导致多药 (≥5种药物).
研究的目的:
- 估计和比较AD诊断前一年的多药性患病率,与非AD个体相比.
- 分析不同时期和不同人口统计数据中多药房流行趋势.
主要方法:
- 一个匹配的横截面设计使用了IADB.nl处方数据库 (1994-2021).
- 包括65岁以上的个人,有阿尔茨海默症药物处方;对照组与年龄和性别相匹配9: 1.
- 分析按时间段 (≤2010和>2010),性别和年龄组分层.
主要成果:
- 4150个AD个体与37,350个对照进行了匹配.
- 艾滋病患者表现出更高的多药性流行率:OR 1.15 (≤2010) 和OR 1.25 (>2010).
- 患有阿尔茨海默症的女性的多药性几率略高;在65-74岁的年龄组中观察到的几率最高.
结论:
- 荷兰的阿尔茨海默病患者在诊断前有明显更高的多药性流行率.
- 这些发现强调了在阿尔茨海默病中管理并发症的挑战,需要药物审查和非药物干预.
- 优化药物治疗方案和结合非药物疗法可以改善AD患者的结果和生活质量.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
相关概念视频
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:28Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:19Pharmacovigilance
771
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
771
01:30Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94